Therefore, concurrent use of St John’s wort and anti-cancer agents that are substrates of CYP3A4 and/or ABCB1 can result in a clinically significant pharmacokinetic interaction and unwanted therapeutic outcome [37]. The gene discussed is ABCB1; the disease is cancer.